Inhibrx gains after insider purchases from CEO [Seeking Alpha]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Seeking Alpha
The transaction conducted on Tuesday raised Lappe's stake in Inhibrx ( INBX ) by ~5% to 801.4K shares. According to a regulatory filing on Thursday, Lappe's transaction was valued at $518.3K, with shares bought at an average of $12.96. Lappe, a co-founder of Inhibrx ( INBX ), has led the company since its inception. Inhibrx ( INBX ) began trading on Nasdaq as an independent company in May following the spinoff from its former parent, Inhibrx, Inc. Early this year, Sanofi ( SNY ) agreed to acquire Inhibrx, Inc., and its experimental therapy SAR447537 targeted alpha-1 antitrypsin (AAT) deficiency, a rare genetic condition. The transaction completed in May left its subsidiary Inhibrx Biosciences ( INBX ) with two experimental cancer therapies, INBRX-109 and INBRX-106. Recommended For You More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx, Inc. (NASDAQ: INBX) had its "market perform" rating re-affirmed by analysts at JMP Securities.MarketBeat
- Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal CancerPR Newswire
- Inhibrx Biosciences Announces Loan Agreement with Oxford FinancePR Newswire
- The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares [Yahoo! Finance]Yahoo! Finance
INBX
Earnings
- 2/28/24 - Miss
INBX
Sec Filings
- 2/4/25 - Form SCHEDULE
- 1/21/25 - Form 424B3
- 1/21/25 - Form 8-K
- INBX's page on the SEC website